-
1
-
-
70349868389
-
Survival of Cancer Patients in Europe, 1995-2002: The EUROCARE 4 Study
-
EUROCARE 4 Edited by Riccardo Capocaccia et al.
-
EUROCARE 4. Survival of cancer patients in Europe, 1995-2002: the EUROCARE 4 study. Edited by Riccardo Capocaccia et al. Eur J Cancer. 2009;45:901-1094.
-
(2009)
Eur J Cancer
, vol.45
, pp. 901-1094
-
-
-
2
-
-
24044554727
-
-
National Comprehensive Cancer Network (NCCN) Accessed 1 Mar 2002
-
National Comprehensive Cancer Network (NCCN). Practice guidelines in oncology, 2002. http://www.nccn.org. Accessed 1 Mar 2002.
-
(2002)
Practice Guidelines in Oncology
-
-
-
3
-
-
45149119734
-
Primary breast cancer: ESMO clinical recommentations for diagnosis, treatment and follow-up
-
18456775 10.1093/annonc/mdn071
-
Pestalozzi B, Castiglione M. Primary breast cancer: ESMO clinical recommentations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl 2):ii7-9.
-
(2008)
Ann Oncol
, vol.19
, Issue.SUPPL. 2
-
-
Pestalozzi, B.1
Castiglione, M.2
-
4
-
-
35348893230
-
Consensus meeting on sentinel lymph node biopsy in breast cancer. Spanish society of mastology and breast disease
-
17916284 10.1016/S0009-739X(07)71689-5
-
Piñero A, Giménez J, Merck B, et al. Consensus meeting on sentinel lymph node biopsy in breast cancer. Spanish society of mastology and breast disease. Cir Esp. 2007;82:146-9.
-
(2007)
Cir Esp
, vol.82
, pp. 146-149
-
-
Piñero, A.1
Giménez, J.2
Merck, B.3
-
5
-
-
0038688702
-
Doxorubicin in combination with fluorouracil and cyclophosphamide (iv FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (iv CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: A study by the GEICAM group
-
12796019 10.1093/annonc/mdg260 1:STN:280:DC%2BD3s3mvFGnsw%3D%3D
-
Martin M, Villar A, Sole-Calvo A, et al. Doxorubicin in combination with fluorouracil and cyclophosphamide (iv FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (iv CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol. 2003;14:833-42.
-
(2003)
Ann Oncol
, vol.14
, pp. 833-842
-
-
Martin, M.1
Villar, A.2
Sole-Calvo, A.3
-
6
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
-
Early Breast Cancer Trialists' Collaborative Group
-
Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717.
-
(2005)
Lancet
, vol.365
, Issue.9472
, pp. 1687-1717
-
-
-
7
-
-
4344682178
-
Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) phase III study
-
15226326 10.1200/JCO.2004.08.125 1:CAS:528:DC%2BD2cXpsVWksL8%3D
-
Alba E, Martín M, Ramos M, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol. 2004;22:2587-93.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2587-2593
-
-
Alba, E.1
Martín, M.2
Ramos, M.3
-
8
-
-
21144435932
-
Adjuvant docetaxel for node-positive breast cancer
-
15930421 10.1056/NEJMoa043681 1:CAS:528:DC%2BD2MXksl2lt7c%3D
-
Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302-13.
-
(2005)
N Engl J Med
, vol.352
, pp. 2302-2313
-
-
Martin, M.1
Pienkowski, T.2
Mackey, J.3
-
9
-
-
0037687355
-
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
-
10.1200/JCO.2003.09.081
-
Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;2:1431-9.
-
(2003)
J Clin Oncol
, vol.2
, pp. 1431-1439
-
-
Citron, M.L.1
Berry, D.A.2
Cirrincione, C.3
-
10
-
-
0033549344
-
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
-
10376613 10.1016/S0140-6736(99)05036-9 1:CAS:528:DyaK1MXkt1Cnsrk%3D
-
Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993-2000.
-
(1999)
Lancet
, vol.353
, Issue.9169
, pp. 1993-2000
-
-
Fisher, B.1
Dignam, J.2
Wolmark, N.3
-
11
-
-
10744223655
-
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
-
15014181 10.1056/NEJMoa040331 1:CAS:528:DC%2BD2cXitV2qtbc%3D
-
Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-92.
-
(2004)
N Engl J Med
, vol.350
, pp. 1081-1092
-
-
Coombes, R.C.1
Hall, E.2
Gibson, L.J.3
-
12
-
-
7444259675
-
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
-
14551341 10.1056/NEJMoa032312 1:CAS:528:DC%2BD3sXosl2gtbc%3D
-
Goss PE, Ingle JN, Silvana Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-802.
-
(2003)
N Engl J Med
, vol.349
, pp. 1793-1802
-
-
Goss, P.E.1
Ingle, J.N.2
Silvana Martino, S.3
-
13
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F
-
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-84.
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
-
14
-
-
0038505539
-
Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe
-
12845683 10.1002/ijc.11226 1:CAS:528:DC%2BD3sXlvF2hsrg%3D
-
Sant M, Allemani C, Capocaccia R, et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer. 2003;106:416-22.
-
(2003)
Int J Cancer
, vol.106
, pp. 416-422
-
-
Sant, M.1
Allemani, C.2
Capocaccia, R.3
-
15
-
-
77950591504
-
Vera Peters and the conservative management of early-stage breast cancer
-
20404978 10.3747/co.v17i2.467 1:STN:280:DC%2BC3c3nsVKrtA%3D%3D
-
Cowan DH. Vera Peters and the conservative management of early-stage breast cancer. Curr Oncol. 2010;17:50-4.
-
(2010)
Curr Oncol
, vol.17
, pp. 50-54
-
-
Cowan, D.H.1
|